New data advance understanding of hypertensive disorders of pregnancy and confirm the economic value of targeted prevention strategies
Mirvie, a company dedicated to bringing a personalized, predictive, and preventive standard of care to pregnancy complications, today announced that two abstracts featuring data from its research programs will be presented as posters at the 2026 Society for Maternal-Fetal Medicine (SMFM) Annual Meeting. These presentations build on Mirvie’s robust clinical research portfolio demonstrating the utility of the company’s RNA-based preeclampsia risk screening test to predict pregnancy complications months before symptoms appear. Together, the posters highlight the importance of biological insights enabled by RNA-based screening and the economic value of earlier, more targeted intervention for preeclampsia.
Poster Presentation Details
Location: Exhibit Hall, Caesar’s Forum, Las Vegas, NV
Date/Time: Thursday, February 12, 2026 from 3:30 PM - 5:00 PM PT
New data show that among individuals with preexisting hypertension who develop preterm preeclampsia, PAPPA2 expression is not elevated, in contrast to what is observed in other patient populations. Notably, individuals with recurrent preterm preeclampsia exhibit PAPPA2 expression patterns during pregnancy that closely correlate with those seen in individuals experiencing preeclampsia for the first time. These findings reinforce that preeclampsia comprises distinct molecular subtypes that are readily measured by RNA-based blood testing, and that these differences are informative for predicting preeclampsia risk.
The data further confirm that hypertensive disorders of pregnancy are biologically heterogeneous and require precision screening approaches so that care can be tailored to each individual’s unique pregnancy.
“This subset analysis underscores the molecular differences between preeclampsia subtypes, despite the common use of the term as a singular condition,” said Carrie Haverty, Vice President of Medical Affairs at Mirvie, and poster presenter on behalf of the Miracle of Life investigators from 11 clinical centers across the U.S. “While Encompass™ is now available for use in pregnancies without preexisting high-risk conditions, including a history of prior preeclampsia, these data now illuminate a path forward to developing risk screening approaches for individuals with a previous history of preeclampsia.”
Location: Exhibit Hall, Caesar’s Forum, Las Vegas, NV
Date/Time: Thursday, February 12, 2026 from 10:30 AM - 12:00 PM PT
This abstract validated the economic impact of introducing Encompass in pregnancies among individuals aged 35 and older with no preexisting high-risk factors. With costs of preeclampsia care reaching billions of dollars annually, identifying cost-effective predictive and prevention strategies are essential to improving outcomes and decreasing costs resulting from preterm births due to preeclampsia.
Using U.S. commercial claims data and a payer-perspective budget impact model, the analysis found that Encompass enables more precise risk prediction and more targeted preventive intervention compared with current USPSTF guideline–based screening. Improvements in risk stratification translated into meaningful reductions in both maternal and neonatal costs yielding a 3:1 economic return to a payer.
The budget impact model estimates at least $56 million in gross savings per 10,000 advanced maternal age pregnancies tested, driven largely by avoided neonatal intensive care utilization and reduced complications associated with preterm preeclampsia.
“Taken together, these posters highlight important progress toward closing gaps in care that contribute to the rising incidence and cost of preeclampsia,” said Kara Boeldt, Founder of EndPreeclampsia. “For too long, we have known that preeclampsia is not a one-size-fits-all condition.. Now we have both clinical and economic data that support the use of tailored care pathways.”
Mirvie is bringing a personalized, predictive, and preventive approach to pregnancy health by using RNA to predict the risk of serious complications such as preeclampsia, preterm birth, and fetal growth restriction months in advance. Backed by rigorous clinical research, Mirvie’s proprietary RNA platform reveals actionable insights into the unique biology of a pregnancy through a simple blood test, enabling care teams to intervene earlier—before complications become life-altering crises.
Serious pregnancy complications affect one in five pregnancies in the U.S., and Mirvie is committed to creating a future in which every pregnancy is as safe and healthy as possible. Mirvie is backed by leading investors including Blackrock, Decheng Capital, Foresite Capital, General Catalyst, GV, Khosla Ventures, and Mayfield.
Encompass™ is available at encompasstest.com/get-the-test
